RBC Capital Remains a Buy on Praxis Precision Medicines (PRAX)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Leonid Timashev maintained a Buy rating on Praxis Precision Medicines (PRAX) with a $449 price target. This follows a June 30 report where Guggenheim also issued a Buy, while Wells Fargo assigned a Hold rating to the stock.
RBC Capital analyst Leonid Timashev maintained a Buy rating on Praxis Precision Medicines yesterday and set a price target of $449.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Timashev is a 5-star analyst with an average return of 27.9% and a 62.34% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Revolution Medicines, and ADC Therapeutics.
In addition to RBC Capital, Praxis Precision Medicines also received a Buy from Guggenheim’s Yatin Suneja in a report issued on June 30. However, on the same day, Wells Fargo assigned a Hold rating to Praxis Precision Medicines (NASDAQ: PRAX).